Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30081325HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041163HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041164HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041165HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041166HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041167HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041168HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS30041169HIVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS20014871HPVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TVIS20014874HPVENSG00000070770.10protein_codingCSNK2A2NoNo1459P19784
TCGA Plot Options
Drug Information
GeneCSNK2A2
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0003984
UniProt IDP19784
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830